reports
Immunocore to report fourth quarter and full year 2025 financial resul...
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year e...
Transgene Announces Financial Calendar for 2026
Transgene Announces Financial Calendar for 2026 Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026: 2025 Fiscal Year Results April 29, 2026: First Quarter 2026 Financial Results May 13, 2026: Annual Shareholders’ Meeting September 24, 2026: First Half 2026 Financial Results November 9, 2026: ...
Transgene présente son calendrier de communication financière pour 202...
Transgene présente son calendrier de communication financière pour 2026 Strasbourg (France), le 4 février 2026, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd'hui son calendrier de communication financière pour 2026 et la date de son Assemblée générale annuelle : 24 mars 2026 : Résultats annuels de l’exercice 2025 29 avril 2026 : Résultats financiers du premier trimestre 2026 13 mai 2026 : Assembl...
Immunocore announces R&D leadership evolution
Immunocore announces R&D leadership evolution Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 30 January 2026) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that Dr. David Berman, E...
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin Mainz, Deutschland, 28. Januar 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Kylie Jimenez mit Wirkung zum 1. März 2026 zur Personalvorständin (Chief People Officer, „CPO“) ernannt hat. Die Ernennung folgt konsequent der strategischen Ausrichtung BioNTechs, um sich bis 2030 zu einem Onkologieunternehmen mit mehreren zugelassenen Produkten zu entwickeln, und unterstreicht die Bedeutung der globalen, hochqualifizierten Belegschaft des Unternehmens, um dieses Ziel z...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with BioNTech’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jim...
Transgene Further Strengthens Scientific Advisory Board with Appointme...
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific advisors to its Scientific Advisory Board, Prof. Antoine Italiano, MD, PhD, and Prof. Ignacio Melero, MD, PhD, further strengthening its scientific leadership. “Antoine and Ignacio are world leaders...
Transgene renforce son comité scientifique avec l’arrivée d’Antoine It...
Transgene renforce son comité scientifique avec l’arrivée d’Antoine Italiano et Ignacio Melero, deux experts renommés en immunothérapie du cancer Strasbourg, France, 23 janvier 2026, 8 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce la nomination de deux nouveaux experts au sein de son comité scientifique, le Prof Antoine Italiano, MD, PhD, et le Prof Ignacio Melero, MD, PhD, renforçant ainsi son leadership scientifique. « Reconnus internationalement pour leur leader...
- Oliver Metzger
- Stephane Houri
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
CBK COMMERZBANK AG
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
WTB WHITBREAD PLC
LXS LANXESS AG
MRK MERCK KGAA
BOSS HUGO BOSS AG
BAS BASF SE
CAP CAPGEMINI SE
AIXA AIXTRON SE
SQN SWISSQUOTE GROUP HOLDING AG
KGX KION GROUP AG
BC BRUNELLO CUCINELLI S.P.A.
FTG111 FLATEXDEGIRO AG
SIE SIEMENS AG
SHL SIEMENS HEALTHINEERS AG
MRNA MODERNA INC.
BNTX BIONTECH SE
ENR SIEMENS ENERGY AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ZAB ZABKA GROUP
PFSE PFISTERER HOLDING SE
- Oliver Metzger
- Stephane Houri
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
CBK COMMERZBANK AG
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
WTB WHITBREAD PLC
LXS LANXESS AG
MRK MERCK KGAA
BOSS HUGO BOSS AG
BAS BASF SE
CAP CAPGEMINI SE
AIXA AIXTRON SE
SQN SWISSQUOTE GROUP HOLDING AG
KGX KION GROUP AG
BC BRUNELLO CUCINELLI S.P.A.
FTG111 FLATEXDEGIRO AG
SIE SIEMENS AG
SHL SIEMENS HEALTHINEERS AG
MRNA MODERNA INC.
BNTX BIONTECH SE
ENR SIEMENS ENERGY AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ZAB ZABKA GROUP
PFSE PFISTERER HOLDING SE
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Martial Descoutures
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as o...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025 Strasbourg, January 12, 2026 – 06:00 p.m. CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2025, the following resources were managed through the liquidity account: 304,479 shares€ 147,574.00 In the second half of 2025, a total of: Purchases348,958 shares€ 389,221.00988 market transactionsSales372,229 shares€ 424,419.001,278 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resour...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décembre 2025 Strasbourg, le 12 janvier 2026 – 18h00 Au titre du contrat de liquidité confié par Transgene à Natixis Oddo BHF SCA, à la date du 31 décembre 2025, les moyens suivants figuraient au compte de liquidité : 304 479 titres Transgene147 574 € Au cours du second semestre 2025, il a été négocié un total de : Achat348 958 titres389 221 €988 transactionsVente372 229 titres424 419 €1 278 transactions Il est rappelé que lors de la mise en place du programme de liquidité en 2016, les moyens suivan...
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Upda...
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026 2026 soll für BioNTech ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) werden, unter anderem durch weitere Fortschritte bei Pipeline-Kandidaten, die sich bereits in der späten klinischen Entwicklung befinden und Immunmodulatoren, Antikörper-Wirkstoff-Konjugate sowie mRNA-Krebsimmuntherapien abdeckenZu den erwarteten Meilensteinen in der Onkologie zählen im Jahr 2026 sieben Datenveröffentlichungen aus der späten klinischen Entwicklung sow...
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of...
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year endAdditional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumor types, building BioNTech into a multi-product ...
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Mor...
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp combinations in ovarian and lun...
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Prev...
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehensive analysis of both the clinical and ...
Transgene publie les données de Phase I confirmant le potentiel de TG4...
Transgene publie les données de Phase I confirmant le potentiel de TG4050 à réduire le risque de récidive des cancers de la tête et du cou TG4050 induit de fortes réponses T CD8 cytotoxiques, spécifiques de plusieurs néoantigènes contenus dans le vaccin thérapeutiqueCes cellules présentent des marqueurs suggérant une potentielle activité à long terme Ces résultats confirment le potentiel de TG4050 en tant qu’immunothérapie individualisée contre le cancer Strasbourg, France, 9 janvier 2026, 8 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.